Marshall Wace
INBX icon

Marshall Wace’s Inhibrx INBX Stock Holding History

Marshall Wace’s Portfolio INBX Stock Details INBX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$834K Sell
8,800
-12,088
-58% -$1.21M ﹤0.01% 2292
2026
Q1 		$1.4M Sell
20,888
-8,422
-29% -$625K ﹤0.01% 1966
2025
Q4 		$2.32M Buy
29,310
+2,068
+8% +$141K ﹤0.01% 1507
2025
Q3 		$918K Buy
+27,242
New +$671K ﹤0.01% 1972
2025
Q1 		– Sell
-53,586
Closed -$825K – 2843
2024
Q4 		$825K Sell
53,586
-37,061
-41% -$564K ﹤0.01% 1819
2024
Q3 		$1.42M Sell
90,647
-106,853
-54% -$1.5M ﹤0.01% 1508
2024
Q2 		$2.8M Buy
+197,500
New +$3.09M ﹤0.01% 1220

Other funds holding INBX

Morgan Stanley
Morgan Stanley New York $1.89T AUM 35.08% 1-Year Est. Return
PA
Perceptive Advisors New York $6.66B AUM 360.84% 1-Year Est. Return
S
Sanofi Paris, France $534M AUM 205.96% 1-Year Est. Return
Viking Global Investors
Viking Global Investors Stamford, Connecticut $35.1B AUM 21.36% 1-Year Est. Return
HighTower Advisors
HighTower Advisors Chicago, Illinois $104B AUM 28.3% 1-Year Est. Return
Bank of America
Bank of America Charlotte, North Carolina $1.55T AUM 33.47% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
SSA
Schonfeld Strategic Advisors New York $27.9B AUM 51.18% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Marshall Wace's INBX Position: Q2 2026 in Review

Marshall Wace reduced its Inhibrx (INBX) stake by 58% in Q2 2026, selling an estimated $1.21M and leaving 8,800 shares worth $834K. The position accounts for ﹤0.01% of the portfolio, ranked #2292.

Marshall Wace first reported a position in INBX in Q2 2024 and has held it in 7 quarters since. The position peaked at $2.8M in Q2 2024. 162 funds tracked by Wall St. Rank hold INBX as of Q2 2026.

  • Marshall Wace held 8,800 shares of Inhibrx worth $834K as of Q2 2026.
  • Marshall Wace sold 12,088 Inhibrx shares in Q2 2026, an estimated $1.21M.
  • Inhibrx made up ﹤0.01% of Marshall Wace's portfolio in Q2 2026, its #2292 holding.
  • Marshall Wace first reported a position in Inhibrx in Q2 2024 and has held it in 7 quarters since.
  • Marshall Wace's Inhibrx position peaked at $2.8M in Q2 2024.
  • 162 funds tracked by Wall St. Rank held Inhibrx as of Q2 2026.

Based on Marshall Wace's 13F filing for Q2 2026, filed 13 Aug 2026.